Statistiche di base
| CIK | 1549595 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nurix Therapeutics, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 3, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi |
|
| September 3, 2025 |
nurixinvestorpresentatio Protein Degraders to Outmatch Cancer and Autoimmune Disease Investor Presentation September 2025 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 19, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiza |
|
| July 9, 2025 |
Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM) Secured $15M license fee as Sanofi extends |
|
| July 9, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO SUBLEASE Nurix Contract No. 11791 THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) dated May 31, 2025 (the “Effective Date”) is made by and between Janssen Research & |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| June 12, 2025 |
ehainvestorconferencecal Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from EHA European Hematological Association Investor Event June 12, 2025 This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 12, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| June 12, 2025 |
[Nurix Logo] Exhibit 99.1 Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in p |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| April 8, 2025 |
Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15M license extension fee from ongoing collaboration with Sanofi Enhanced oversi |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| April 8, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUBLEASE by and between Janssen Research & Development, LLC, a New Jersey limited liability company and Nurix Therapeutics, Inc., a Delaware corporation SUBLEASE THIS SUBLEASE (“Sublease”) |
|
| March 28, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| March 13, 2025 |
Exhibit 99.1 [Nurix Logo] Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors Dr. Baynes has been a member of Nurix’s Medical Advisory Board since 2023 SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci |
|
| March 13, 2025 |
March 13, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Eric Atallah Kevin Kuhar Re: Nurix Therapeutics, Inc. Form 10-K for Fiscal Year Ended November 30, 2024 File No. 001-39398 Ladies and Gentlemen: We are submitting this letter on behalf of Nurix Therapeutics, Inc. (the “Company”) i |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat |
|
| February 14, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| January 28, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 28, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| January 28, 2025 |
[Nurix logo] Exhibit 99.1 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received PRIME designation from the European Medicines Agency for NX-5948 |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39398 NURIX THERAPEUT |
|
| January 28, 2025 |
Calculation of Filing Fee Tables S-8 Nurix Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share Other 3,036,376 $ 19.69 $ 59,786,243.44 0.0001531 $ 9,153.27 2 Equi |
|
| January 28, 2025 |
As filed with the Securities and Exchange Commission on January 28, 2025 As filed with the Securities and Exchange Commission on January 28, 2025 Registration No. |
|
| January 28, 2025 |
Exhibit 19.1 INSIDER TRADING POLICY THIS POLICY WAS APPROVED BY THE BOARD ON JANUARY 22, 2025 PURPOSE Nurix Therapeutics, Inc. (“Nurix”) believes our stock is valuable. For that reason, Nurix stock options and discounted sales of Nurix stock through our Employee Stock Purchase Plan (“ESPP”) are important parts of our compensation program. If you choose to invest in Nurix stock, there are some rule |
|
| January 13, 2025 |
Exhibit 99.1 [Nurix Logo] Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 in additional cancer indications and inflammatory diseases Advance o |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| January 13, 2025 |
Medicines to Outmatch Disease Investor Presentation January 13, 2025 Exhibit 99.2 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipate,” “believe,” “c |
|
| December 10, 2024 |
EX-99.1 2 nrix20241210formex991ashda.htm EX-99.1 Exhibit 99.1 [Nurix logo] Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patien |
|
| December 10, 2024 |
Nurix Therapeutics Blazing a New Path in Medicine American Society of Hematology Investor Event December 9, 2024 Exhibit 99. |
|
| December 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 9, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| November 14, 2024 |
NRIX / Nurix Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427858d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Nurix therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 67080M103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 14, 2024 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Nurix Therapeutics, In |
|
| November 14, 2024 |
NRIX / Nurix Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm2426483d9sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 3)* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67080M103 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| November 14, 2024 |
SC 13G/A 1 ea0220738-sc13ga1sandsnurix.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per shares (Title of Class of Securities) 67080M103 (CUSIP Number) September 30, 2024 (Date of Event Which |
|
| November 8, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67080M103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Nurix Therapeutics, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1( |
|
| October 31, 2024 |
Up to $300,000,000 Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-280117 PROSPECTUS SUPPLEMENT (To Prospectus dated June 11, 2024) Up to $300,000,000 Common Stock We previously entered into an Equity Distribution Agreement dated August 4, 2021, as amended by Amendment No. 1 to the Equity Distribution Agreement dated July 11, 2024 and Amendment No. 2 to the Equity Distribution Agreement dated |
|
| October 31, 2024 |
As filed with the Securities and Exchange Commission on October 31, 2024 As filed with the Securities and Exchange Commission on October 31, 2024 Registration No. |
|
| October 31, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0 |
|
| October 31, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form 424(b)(5) (Form Type) Nurix Therapeutics, Inc. |
|
| October 31, 2024 |
2024 Equity Inducement Plan and forms of award agreements Exhibit 99.1 NURIX THERAPEUTICS, INC. 2024 EQUITY INDUCEMENT PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’s future perfor |
|
| October 31, 2024 |
Exhibit 10.1 AMENDMENT NO. 2 TO THE EQUITY DISTRIBUTION AGREEMENT October 31, 2024 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: This Amendment No. 2 to the Equity Distribution Agreement (this “Amendment”) is entered into as of the date first written above by Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), and Piper S |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 15, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| October 16, 2024 |
Exhibit 99.1 Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur SAN FRANCISCO, October 16, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointme |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| October 11, 2024 |
Exhibit 10.4 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of September 13, 2024 (“Effective Date”), by and between ARE-SAN FRANCISCO NO. 19 OWNER, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated |
|
| October 11, 2024 |
, by and between ARE-San Francisco No. 26 Owner, LLC and the Registrant Exhibit 10.2 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this “Fourth Amendment”) is made as of April 30, 2021, by and between ARE-SAN FRANCISCO NO. 26, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation, formerly known as Nurix, Inc. (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement d |
|
| October 11, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 11, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| October 11, 2024 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of March 2, 2021, by and between ARE-SAN FRANCISCO NO. 26, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation, formerly known as Nurix, Inc. (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated |
|
| October 11, 2024 |
Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s macroglobulinemia, follicular lymphoma and marginal zone lymphoma patien |
|
| October 11, 2024 |
Exhibit 10.3 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) is made as of September 13, 2024 (“Effective Date”), by and between ARE-SAN FRANCISCO NO. 26 OWNER, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated |
|
| September 5, 2024 |
Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation September 2024 2 Important notice and disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| September 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi |
|
| July 11, 2024 |
Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phi |
|
| July 11, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form 424(b)(5) (Form Type) Nurix Therapeutics, Inc. |
|
| July 11, 2024 |
Up to $150,000,000 Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-280117 PROSPECTUS SUPPLEMENT (To Prospectus dated June 11, 2024) Up to $150,000,000 Common Stock We previously entered into an Equity Distribution Agreement dated August 4, 2021, as amended by Amendment No. 1 to the Equity Distribution Agreement dated July 11, 2024 (Equity Distribution Agreement) with Piper Sandler & Co. (Pipe |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 11, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| July 11, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO THE EQUITY DISTRIBUTION AGREEMENT July 11, 2024 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: This Amendment No. 1 to the Equity Distribution Agreement (this “Amendment”) is entered into as of the date first written above by Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), and Piper Sand |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| June 17, 2024 |
Exhibit 99.1 [Nurix logo] Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses |
|
| June 17, 2024 |
Nurix Therapeutics NX-5948 Clinical Update European Hematology Association Congress EHA2024 June 16, 2024 2 Important notice and disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 16, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| June 11, 2024 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] NURIX THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIE |
|
| June 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Nurix Therapeutics, Inc. |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 Table of Contents As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
Exhibit 4.4 NURIX THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITI |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| April 12, 2024 |
EXHIBIT 4.1 NURIX THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: April [•], 2024 Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder” |
|
| April 12, 2024 |
Exhibit 1.1 Execution Version NURIX THERAPEUTICS, INC. 10,166,667 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,500,100 Shares of Common Stock Underwriting Agreement April 11, 2024 J.P. Morgan Securities LLC Piper Sandler & Co. Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madiso |
|
| April 12, 2024 |
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering EXHIBIT 99.1 Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering SAN FRANCISCO, April 11, 2024 – Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share. In addition, and in lieu of common stock, Nurix is offering to certain invest |
|
| April 12, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258448 PROSPECTUS SUPPLEMENT (To prospectus dated April 6, 2023) 10,166,667 shares of common stock Pre-funded warrants to purchase 1,500,100 shares of common stock We are offering 10,166,667 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of co |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 11, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat |
|
| April 11, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258448 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanyi |
|
| April 10, 2024 |
Exhibit 10.2 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of March 25, 2024 (“Effective Date”), by and between ARE-SAN FRANCISCO NO. 19 OWNER, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into that certain Lease Agreement dated as of J |
|
| April 10, 2024 |
Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case studies on NX-5948 demonstrating clinical responses in patients with CNS lym |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| April 10, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SIXTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Sixth Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of March 6, 2024 (the “Amendment Dat |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 10, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 9, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| March 27, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| March 11, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat |
|
| March 11, 2024 |
Exhibit 99.1 [Nurix logo] Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial Nurix cleared to introduce new chirally controlled NX-2127 drug product and resume enrollment of new patients into the study SAN FRANCISCO, March 11, 2024 – Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation dru |
|
| February 15, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 |
|
| February 15, 2024 |
Exhibit 10.24 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Fifth Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of November 3, 2023 (the “Amendment |
|
| February 15, 2024 |
Exhibit 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENT by and between NURIX THERAPEUTICS, INC. and SEAGEN INC. dated as of September 6, 2023 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 ARTICLE 2 DEGRADER TARGE |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39398 NURIX THERAPEUT |
|
| February 15, 2024 |
Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update NX-5948 received fast track designation from the FDA NX-5948 showed positive results in Phase 1 clinical trial establishing a robust foundation for advancement in CLL Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader o |
|
| February 15, 2024 |
As filed with the Securities and Exchange Commission on February 15, 2024 As filed with the Securities and Exchange Commission on February 15, 2024 Registration No. |
|
| February 15, 2024 |
Exhibit 97.1 COMPENSATION RECOVERY POLICY THIS POLICY WAS ADOPTED BY THE BOARD AND IS EFFECTIVE AS OF JULY 25, 2023. PURPOSE The Board of Directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”) has determined that it is in the best interests of the Company and its stockholders to adopt this Compensation Recovery Policy (this “Policy”) to enable the Company to recover from specified cur |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi |
|
| February 14, 2024 |
EX-99.1 2 tm245846d24ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 p |
|
| February 14, 2024 |
NRIX / Nurix Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
NRIX / Nurix Therapeutics, Inc. / SANDS ARTHUR T - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2024 |
NRIX / Nurix Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
NRIX / Nurix Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Nurix therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 13, 2024 |
NRIX / Nurix Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01578-nurixtherapeuticsinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Nurix Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 67080M103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursu |
|
| January 29, 2024 |
NRIX / Nurix Therapeutics, Inc. / ARK Investment Management LLC - SC 13G Passive Investment SC 13G 1 tm244117d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Nurix Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| January 8, 2024 |
nrix-202401088xkex991 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation January 2024 Exhibit 99. |
|
| January 8, 2024 |
Exhibit 99.2 [Nurix logo] Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases Positive Phase 1 data presented at American Society of Hematology supports prioritizing the acceleration of enrollment of NX-5948 in leukemia and lymphoma Strategic collaborations in small molecule, targeted protein degradation w |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiza |
|
| December 11, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 11, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi |
|
| December 11, 2023 |
Exhibit 99.1 [Nurix logo] Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL) Rapid durable complete resp |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi |
|
| November 13, 2023 |
EX-99.1 Exhibit 99.1 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation November 2023 Important notice and disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if u |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| November 1, 2023 |
Exhibit 99.1 Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial Currently enrolled patients may continue receiving NX-2127 SAN FRANCISCO, CA, November 1, 2023 – Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today ann |
|
| October 12, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of June 28, 2023 (the “Effective Date”), by and between ARE-SAN FRANCISCO NO. 19 OWNER, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into that certain Lease Agreement dated as of J |
|
| October 12, 2023 |
Exhibit 10.2 FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this "First Amendment") is made as of August 25, 2023, by and between 8800 TECHNOLOGY FOREST PL, LLC, a Delaware limited liability company ("Landlord"), and NURIX THERAPEUTICS, INC., a Delaware corporation ("Tenant"). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of March |
|
| October 12, 2023 |
Exhibit 99.1 Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced strategic collaboration with Seagen to develop a portfolio of Degrader-Antibody Conjugates, resulting in a $60 million upfront payment Achieved an additional $8 million in research milestones for the quarter, resulting in milestone and license fee payments totaling $35.5 mi |
|
| October 12, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 12, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| October 12, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENT by and between NURIX THERAPEUTICS, INC. and SEAGEN INC. dated as of September 6, 2023 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 ARTICLE 2 DEGRADER TARGET |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 6, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi |
|
| July 13, 2023 |
Exhibit 99.1 Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations Received $20 million licensing payment from Gilead for NX-0479, an oral IRAK4 degrader f |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 13, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organization |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 13, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| April 13, 2023 |
Exhibit 99.1 Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment Expanded therapeutic area potential of protein degradation pipeline with Gilead in rheumatoid arthritis and other inflammatory diseases Achieved a |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 5, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| March 24, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| March 24, 2023 |
nurixtherapeuticsincx20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat |
|
| February 24, 2023 |
NRIX / Nurix Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
SC 13G/A 1 d441085dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Nurix Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Ch |
|
| February 14, 2023 |
NRIX / Nurix Therapeutics, Inc. Common stock / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Nurix Therapeutics, In |
|
| February 14, 2023 |
NRIX / Nurix Therapeutics, Inc. Common stock / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm234999d18sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appro |
|
| February 14, 2023 |
NRIX / Nurix Therapeutics, Inc. Common stock / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Nurix therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 9, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nurix Therapeutics, Inc. |
|
| February 9, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 |
|
| February 9, 2023 |
Exhibit 99.1 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies Achieved significant milestones in wholly owned clinical programs and partnered preclinical programs Maintained strong financial posit |
|
| February 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| February 9, 2023 |
As filed with the Securities and Exchange Commission on February 9, 2023 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2023 Registration No. |
|
| February 9, 2023 |
As filed with the Securities and Exchange Commission on February 9, 2023 As filed with the Securities and Exchange Commission on February 9, 2023 Registration No. |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3939 |
|
| February 9, 2023 |
As filed with the Securities and Exchange Commission on February 9, 2023 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2023 Registration No. |
|
| February 9, 2023 |
Description of Registrant’s Securities Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following summary of the terms of our capital stock is based upon our restated certificate of incorporation, our amended and restated bylaws and applicable provisions of the Delaware General Corporation Law (DGCL). This summary is not complete, and is qualified by reference to our restated certificate of incorporation and our amended and restated bylaws |
|
| January 9, 2023 |
Exhibit 99.2 Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix’s two first-in-class BTK degraders in 2023 Clinical data update planned for |
|
| January 9, 2023 |
Exhibit 99.1 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation January 2023 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in th |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiza |
|
| December 16, 2022 |
Exhibit 3.1 NURIX THERAPEUTICS, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS As Amended and Restated on December 15, 2022 NURIX THERAPEUTICS, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS ARTICLE I: STOCKHOLDERS 1 Section 1.1: Annual Meetings 1 Section 1.2: Special Meetings 1 Section 1.3: Notice of Meetings 1 Section 1.4: Adjournments 1 Section 1.5: Quoru |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 15, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi |
|
| December 13, 2022 |
EX-99.2 Exhibit 99.2 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine ASH Event Presentation December 12, 2022 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or |
|
| December 13, 2022 |
EX-99.1 Exhibit 99.1 Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK mutations conferring resis |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 12, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi |
|
| October 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 26, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| October 26, 2022 |
Exhibit 99.1 Leader in Targeted Protein Modulation The First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic Arthur T. Sands, M.D., Ph.D. President & CEO 5th Annual TPD Summit Boston, MA October 26th, 2022 1 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements wit |
|
| October 26, 2022 |
Exhibit 99.2 Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin?s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation and immunomodulatory activity achieved b |
|
| October 6, 2022 |
Exhibit 10.6 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FOURTH Amendment to collaboration AND LICENSE AGREEMENT This Fourth Amendment to Collaboration and License Agreement (this ?Amendment?) is entered into as of August 11, 2022 (the ?Amendment Date?) by |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| October 6, 2022 |
Exhibit 10.3 SECOND AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENT This Second Amendment to Collaboration, Option and License Agreement (this ?Second Amendment?), dated September 9, 2022 (the ?Second Amendment Effective Date?), is by and between Nurix Therapeutics, Inc., a Delaware corporation (?Nurix?) and Gilead Sciences, Inc., a Delaware corporation (?Gilead?). RECITALS WHEREAS, Gilea |
|
| October 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 6, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiza |
|
| October 6, 2022 |
Exhibit 99.1 Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial position with $413.6 million in cash and marketable securities as of August 31, 2022 Expanded leadership team and board of directors with experienced industry leaders A |
|
| October 6, 2022 |
EX-10.4 4 nrix-ex104180.htm EX-10.4 Exhibit 10.4 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SEcond Amendment to collaboration AND LICENSE AGREEMENT This Second Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of Decem |
|
| October 6, 2022 |
Exhibit 10.2 FIRST AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENT This First Amendment to Collaboration, Option and License Agreement (this ?First Amendment?), dated August 13, 2019 (the ?First Amendment Effective Date?), is by and between Nurix Therapeutics, Inc., a Delaware corporation (?Nurix?) and Gilead Sciences, Inc., a Delaware corporation (?Gilead?). RECITALS WHEREAS, Nurix and G |
|
| October 6, 2022 |
Exhibit 10.5 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD Amendment to collaboration AND LICENSE AGREEMENT This Third Amendment to Collaboration and License Agreement (this ?Amendment?) is entered into as of July 7, 2022 (the ?Amendment Date?) by and |
|
| September 14, 2022 |
Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors Exhibit 99.1 Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors SAN FRANCISCO, September 14, 2022 ? Nurix Therapeutics , Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Edward C. Saltzman to its board of directors. Mr. Saltzman has over 30 years of drug |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 12, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organ |
|
| July 8, 2022 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July [ ], 2022, between Nurix Therapeutics, Inc., a corporation incorporated under the laws of the state of Delaware (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). |
|
| July 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Nurix Therapeutics, Inc. |
|
| July 8, 2022 |
Exhibit 4.1 NURIX THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [?] (subject to adjustment) Warrant No. [?] Original Issue Date: July [?], 2022 Nurix Therapeutics, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [?] or its registered assigns (the ?Holder?) |
|
| July 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Nurix Therapeutics, Inc. |
|
| July 8, 2022 |
Nurix Therapeutics Announces $55 Million Registered Direct Offering Exhibit 99.1 Nurix Therapeutics Announces $55 Million Registered Direct Offering SAN FRANCISCO, July 7, 2022 ? Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with an institutional investor to sell, in a registered direct offering, pre-funded wa |
|
| July 8, 2022 |
Nurix Therapeutics Announces $40 Million Registered Direct Offering Exhibit 99.2 Nurix Therapeutics Announces $40 Million Registered Direct Offering SAN FRANCISCO, July 8, 2022 ? Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two healthcare-focused investment funds to sell, in a registered direct offering, |
|
| July 8, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| July 8, 2022 |
Nurix Therapeutics, Inc. Pre-Funded Warrants to Purchase up to 3,945,480 Shares of Common Stock Table of Contents As filed pursuant to Rule 424(b)(5) Registration No. 333-258448 PROSPECTUS SUPPLEMENT (To prospectus dated August 4, 2021) Nurix Therapeutics, Inc. Pre-Funded Warrants to Purchase up to 3,945,480 Shares of Common Stock We are offering pre-funded warrants (the ?Pre-funded Warrants?) to purchase up to 3,945,480 shares of our common stock, $0.001 par value per share (our ?common sto |
|
| July 8, 2022 |
Nurix Therapeutics, Inc. Pre-Funded Warrants to Purchase up to 2,869,440 Shares of Common Stock Table of Contents As filed pursuant to Rule 424(b)(5) Registration No. 333-258448 PROSPECTUS SUPPLEMENT (To prospectus dated August 4, 2021) Nurix Therapeutics, Inc. Pre-Funded Warrants to Purchase up to 2,869,440 Shares of Common Stock We are offering pre-funded warrants (the ?Pre-funded Warrants?) to purchase up to 2,869,440 shares of our common stock, $0.001 par value per share (our ?common sto |
|
| July 7, 2022 |
Exhibit 99.1 Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-5948 Phase 1a clinical trial for certain B-cell malignancies NX-1607 IND cleared FDA for expansion of enrollment to U.S. clinical sites for patients with solid tumors Res |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| July 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| June 10, 2022 |
NRIX / Nurix Therapeutics, Inc. Common stock / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 26, 2022 |
Exhibit 99.1 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine R&D Day New York, NY May 26, 2022 Welcome and Introduction Arthur T Sands, MD, PhD President, CEO and Board Director Nurix Therapeutics 2 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking state |
|
| May 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| May 26, 2022 |
Exhibit 99.2 Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development Data to be discussed at Nurix R&D Day at 8:00 a.m. ET today May 26 SAN FRANCISCO, May 26, 2022 (GLOBAL NEWSWIRE) ? Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today anno |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| May 6, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organization |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| April 8, 2022 |
Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 1 day of March, 2022 (?Effective Date?), between 8800 TECHNOLOGY FOREST PL, LLC, a Delaware limited liability company (?Landlord?), and NURIX THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: Building 100, 8800 Technology Forest Place, The Woodlands, Texas 77381 Premises: That portion of the Building, comm |
|
| April 7, 2022 |
Exhibit 99.1 Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix?s drug-enhanced tumor infiltrating lymphocyte (TIL) program Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Reports strong financial position with |
|
| April 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 7, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| March 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only ( |
|
| March 25, 2022 |
DEFA14A 1 d509090ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 2, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| March 2, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 1, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| February 14, 2022 |
NRIX / Nurix Therapeutics, Inc. Common stock / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SC 13G 1 tm224436d11sc13g.htm SC 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| February 14, 2022 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 14, 2022 |
Exhibit 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Nurix Therapeutics, Inc.is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2022 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, it |
|
| February 14, 2022 |
NRIX / Nurix Therapeutics, Inc. Common stock / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Nurix therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value per share, of Nurix Therapeutics, In |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Nurix Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2022 |
EXHIBIT 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirec |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2021 (Date of |
|
| February 11, 2022 |
NRIX / Nurix Therapeutics, Inc. Common stock / COLUMN GROUP L P - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* NURIX THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 28, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None. |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39398 NURIX THERAPEUT |
|
| January 28, 2022 |
Employment Agreement, dated July 15, 2020, by and between the Registrant and Hans van Houte Exhibit 10.9 NURIX THERAPEUTICS, INC. July 15, 2020 Hans van Houte c/o Nurix Therapeutics, Inc. RE: Continued Employment with Nurix Therapeutics, Inc. Dear Hans: This employment letter sets forth the terms confirms your continued employment as Chief Financial Officer of Nurix Therapeutics, Inc., a Delaware Corporation (the ?Company? or ?Nurix?). You will continue to report to the Company?s Chief E |
|
| January 28, 2022 |
Exhibit 10.11 NURIX THERAPEUTICS, INC. EXECUTIVE SEVERANCE AND CHANGE IN CONTROL PLAN Amended and Restated January 19, 2022 SECTION 1 PURPOSE The Board of Nurix Therapeutics, Inc., a Delaware corporation (together with its subsidiaries, the ?Company?), considers it in the best interests of the stockholders of the Company to reinforce the continued attention and dedication of certain key employees |
|
| January 28, 2022 |
As filed with the Securities and Exchange Commission on January 28, 2022 As filed with the Securities and Exchange Commission on January 28, 2022 Registration No. |
|
| January 27, 2022 |
Exhibit 99.1 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update Advanced four wholly owned and internally developed programs into clinical development Strengthened balance sheet with year-end cash and investments totaling $433 million Anticipate multiple clinical milestones in 2022 San Francisco, CA, January 27, 2022 ? Nurix Therapeutic |
|
| January 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 27, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| January 10, 2022 |
EX-99.1 2 d279616dex991.htm EX-99.1 Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation January 2022 Exhibit 99.1 Important Notice and Disclaimers This presentation contains information relating to Nurix Therapeutics, Inc. (the “Company,” “we," "us" or "our") and forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation R |
|
| January 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| January 10, 2022 |
Exhibit 99.2 Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts Nurix leads protein modulation field with four active clinical stage programs Anticipates data-rich 2022 with clinical-stage programs and a pipeline fueled by proprietary DELigase platform San Francisco, CA, January 10, 2022 (GLOBE NEWSWIRE) ? Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmac |
|
| October 27, 2021 |
EX-99.1 2 d249587dex991.htm EX-99.1 Nurix Therapeutics Blazing a New Path in Medicine First Demonstration of Targeted Protein Degradation of BTK in Hematologic Malignancies: Initial NX-2127 Phase 1a PK/PD Data 4th Annual Targeted Protein Degradation (TPD) Summit October 27, 2021 Exhibit 99.1 Important Notice and Disclaimers This presentation contains information relating to Nurix Therapeutics, Inc |
|
| October 27, 2021 |
EX-99.2 Exhibit 99.2 Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of mechanism of targeted protein |
|
| October 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| October 14, 2021 |
Employment Agreement, dated June 10, 2021, by and between the Registrant and Stefani Wolff Exhibit 10.1 Via DocuSign June 1, 2021 Stefani Wolff Re: Offer of Employment Dear Stefani: On behalf of Nurix Therapeutics (the ?Company?), I am pleased to invite you to join the Company as Chief Operating Officer and Executive Vice President of Product Development, reporting to Arthur T. Sands, Chief Executive Officer. As we have discussed many aspects of this position, I will attempt to summariz |
|
| October 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| October 14, 2021 |
EX-99.1 2 nrix-ex9916.htm EX-99.1 Exhibit 99.1 Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer Expanded Board of Directors with experienced business leaders Strong financial position with $465.4 million as of August 31, 2021 San Francisco, CA, Oct |
|
| October 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 14, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz |
|
| October 14, 2021 |
Lease Agreement, dated as of June 21, 2021, between ARE-San Francisco No. 19 LLC and the Registrant Exhibit 10.2 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 21st day of June, 2021, between ARE-SAN FRANCISCO NO. 19, LLC, a Delaware limited liability company (?Landlord?), and NURIX THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: 455 Mission Bay Boulevard South, San Francisco, California Premises: That portion of the Building commonly known as Suite 493, consis |
|
| September 30, 2021 |
Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders EX-99.1 2 d225615dex991.htm EX-99.1 Exhibit 99.1 Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders SAN FRANCISCO, September 30, 2021 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of d |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 25, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organ |
|
| August 4, 2021 |
Exhibit 4.4 NURIX THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EXEC |
|
| August 4, 2021 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] NURIX THERAPEUTICS, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MA |
|
| August 4, 2021 |
EX-1.2 Exhibit 1.2 NURIX THERAPEUTICS, INC. EQUITY DISTRIBUTION AGREEMENT August 4, 2021 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Nurix Therapeutics, Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through |
|
| August 4, 2021 |
As filed with the Securities and Exchange Commission on August 4, 2021 S-3ASR 1 d211774ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on August 4, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Nurix Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-0838048 (State or other ju |
|
| July 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 13, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| July 13, 2021 |
EX-99.1 2 nrix-ex9916.htm EX-99.1 Exhibit 99.1 Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three additional wholly owned drug candidates in 2021 Strong financial position with $496 million as |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| July 9, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 8, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati |
|
| June 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 2, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| June 2, 2021 |
EX-99.2 3 d152875dex992.htm EX-99.2 Log2 Fold change BTK Proteomics Study NX-5948 selectively degrades BTK in TMD8 cells. Cells were treated with DMSO or NX-5948 (50 nM) for 6 hours in triplicate. Effects on protein levels were analyzed using label-free proteomics. Copyright © 2021 Nurix Therapeutics, Inc. Contact: [email protected] Daniel W Robbins, Mark Noviski, May Tan, Cristiana Guiducci, T |
|
| June 2, 2021 |
Exhibit 99.1 Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease Orally available NX-5948 is a potent selective degrader of Bruton?s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 28, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| June 1, 2021 |
Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors Exhibit 99.1 Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors SAN FRANCISCO, June 1, 2021 (GLOBE NEWSWIRE) ? Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors. Dr. Siegall is a co-founder of Seagen Inc. (formerl |
|
| May 10, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organization |
|
| April 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 13, 2021 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat |
|
| April 13, 2021 |
Exhibit 99.1 Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after successful $150 million follow-on offering in March 2021 San Francisco, CA, April 13, 20 |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 5, 2021 |
4,500,000 shares Common stock J.P. Morgan Piper Sandler Stifel RBC Capital Markets Needham & Company Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-253783 Prospectus 4,500,000 shares Common stock We are offering 4,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol ?NRIX.? The last reported sale price of our common stock on the Nasdaq Global Market on March 4, 2021 was $32.49 per share. We are an ?emerging growth com |
|
| March 5, 2021 |
As filed with the Securities and Exchange Commission on March 5, 2021 Registration No. |
|
| March 2, 2021 |
Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco, CA 94158 March 2, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Tim Buchmiller Re: Nurix Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-253783) originally filed March 2, 2021. Requested D |
|
| March 2, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 2, 2021. |
|
| March 2, 2021 |
J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Piper Sandler & Co. 345 Park Avenue, Suite 1200 New York, New York 10154 Stifel, Nicolaus & Company, Incorporated One South Street, 15th Floor Baltimore, Maryland 21202 March 2, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, |
|
| March 2, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 NURIX THERAPEUTICS, INC. [?] Shares of Common Stock Underwriting Agreement March [?], 2021 J.P. Morgan Securities LLC Piper Sandler & Co. Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Piper Sandler & Co. 345 Park Avenue, Suite 1200 New Yor |
|
| February 22, 2021 |
Table of Contents Confidential Treatment Requested by Nurix Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on February 22, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED |
|
| February 16, 2021 |
EX-99.1 2 nrix-ex9919.htm EX-99.1 Exhibit 99.1 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies Three additional wholly owned programs expected to enter clinical trials in 2021 Expanded Sanofi collaboration |
